Medical School

  • Tufts University School of Medicine , 1990 , Boston , MA


  • Children's National Medical Center , Washington , DC


Pediatric Oncology Research Fellowship; Pharmacology and Experimental section, BOB
  • National Cancer Institute (NCI) , Bethesda , MD


Dr. Warren is an internationally recognized expert in pediatric neuro-oncology. She was appointed Clinical Director of the Stop & Shop Family Pediatric Brain Tumor Program in the Department of Pediatric Oncology in 2019 and was previously Senior Investigator and head of the Neuro-Oncology Section in the Pediatric Oncology branch of the National Cancer Institute where she worked for more than 25 years. Her major focus is developing new therapeutics to improve the outcome and quality of life for children with CNS tumors. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery. Her clinical trials have led the field in exploring new approaches for the treatment of children with these diseases. Dr. Warren has extensive experience in pharmacology, neuro-imaging, and clinical trial design and incorporates each of these into her research. She has led a number of clinical trials, including single institution, multi-institution, national consortium, and international trials.

Dr. Warren currently serves as the chair of RAPNO (Response Assessment in Pediatric Neuro-Oncology), a member of the NCI Brain Malignancy Steering Committee, NCI Clinical Trials, and Translational Research Advisory Committee Ad hoc Working Group on Glioblastoma, and is a steering committee member for the DIPG Registry. She has served on numerous national and international scientific committees and advisory boards.


  • American Board of Pediatrics, General Pediatrics


Publications powered by Harvard Catalyst Profiles

  1. Rodgers LT, Lester McCully CM, Odabas A, Cruz R, Peer CJ, Figg WD, Warren KE. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemother Pharmacol. 2020 Jan 01. View abstract
  2. Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2019 Dec 04. View abstract
  3. Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn P, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem R, Geraghty AC, Ni L, Andreasson KI, Vitanza NA, Warren KE, Thomas CJ, Monje M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019 Nov 20; 11(519). View abstract
  4. Heiss JD, Jamshidi A, Shah S, Martin S, Wolters PL, Argersinger DP, Warren KE, Lonser RR. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J Neurosurg Pediatr. 2018 12 07; 23(3):333-342. View abstract
  5. Withrow DR, de Gonzalez AB, Lam CJK, Warren KE, Shiels MS. Trends in Pediatric Central Nervous System Tumor Incidence in the United States, 1998-2013. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):522-530. View abstract
  6. Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, Gupta N, Myseros JS, Hwang EI, Kline C, Crawford JR, Warren KE, Cha S, Liang WS, Berens ME, Packer RJ, Resnick AC, Prados M, Mueller S, Nazarian J. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clin Cancer Res. 2018 12 01; 24(23):5850-5859. View abstract
  7. Morales La Madrid A, Ranjan S, Warren KE. Gliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22-23, 2017, Bethesda, USA. J Neurooncol. 2018 Oct; 140(1):1-4. View abstract
  8. Warren KE. Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma. Front Oncol. 2018; 8:239. View abstract
  9. Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, Warren KE. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018 08 09; 132(6):662-666. View abstract
  10. Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018 06 18; 20(7):897-906. View abstract
  11. Wen LS, Warren KE. Combatting the opioid epidemic: Baltimore's experience and lessons learned. J Public Health (Oxf). 2018 06 01; 40(2):e107-e111. View abstract
  12. Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res. 2018 10 15; 24(20):4921-4930. View abstract
  13. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih CS, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren AO, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018 07 01; 36(19):1963-1972. View abstract
  14. Nellan A, Rota C, Majzner R, Lester-McCully CM, Griesinger AM, Mulcahy Levy JM, Foreman NK, Warren KE, Lee DW. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018 04 30; 6(1):30. View abstract
  15. Jack HE, Warren KE, Sundaram S, Gheihman G, Weems J, Raja AS, Miller ES. Making Naloxone Rescue Part of Basic Life Support Training for Medical Students. AEM Educ Train. 2018 Apr; 2(2):174-177. View abstract
  16. Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018 01 22; 20(2):160-173. View abstract
  17. Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2018 01 10; 20(1):13-23. View abstract
  18. Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Packer RJ, Kieran MW. Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee". Neuro Oncol. 2018 01 10; 20(1):144-145. View abstract
  19. Dang Do AN, Baker EH, Warren KE, Bianconi SE, Porter FD. Spontaneously regressing brain lesions in Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2018 02; 176(2):386-390. View abstract
  20. Cooney T, Lane A, Bartels U, Bouffet E, Goldman S, Leary SES, Foreman NK, Packer RJ, Broniscer A, Minturn JE, Shih CS, Chintagumpala M, Hassall T, Gottardo NG, Dholaria H, Hoffman L, Chaney B, Baugh J, Doughman R, Leach JL, Jones BV, Fouladi M, Warren KE, Monje M. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 2017 09 01; 19(9):1279-1280. View abstract
  21. Warren KE, Wen LS. Measles, social media and surveillance in Baltimore City. J Public Health (Oxf). 2017 09 01; 39(3):e73-e78. View abstract
  22. Ranjan S, Warren KE. Gliomatosis Cerebri: Current Understanding and Controversies. Front Oncol. 2017; 7:165. View abstract
  23. Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017 06 01; 19(6):750-761. View abstract
  24. Warren KE, Tay S, Wen LS. The Role of Public Health in Combatting Synthetic Cannabinoid Use in Adolescents. J Adolesc Health. 2017 May; 60(5):483-486. View abstract
  25. Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 2017 08 01; 400:110-116. View abstract
  26. League-Pascual JC, Lester-McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. J Neurooncol. 2017 05; 132(3):401-407. View abstract
  27. Baugh J, Bartels U, Leach J, Jones B, Chaney B, Warren KE, Kirkendall J, Doughman R, Hawkins C, Miles L, Fuller C, Hassall T, Bouffet E, Lane A, Hargrave D, Grill J, Hoffman LM, Jones C, Towbin A, Savage SA, Monje M, Li XN, Ziegler DS, Veldhuijzen van Zanten S, Kramm CM, van Vuurden DG, Fouladi M. The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. J Neurooncol. 2017 04; 132(2):323-331. View abstract
  28. Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017 01; 133(1):5-12. View abstract
  29. Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, Siu A, Papillon-Cavanagh S, Bechet D, Ligon KL, Ellezam B, Ingram WJ, Stinson C, Moore AS, Warren KE, Karamchandani J, Packer RJ, Jabado N, Majewski J, Nazarian J. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016 Apr 06; 7:11185. View abstract
  30. Warren KE, Tay S, Wen LS. Patient and Public Risks of Powdered Alcohol: A Citywide Case Study to Prevent Abuse. Ann Intern Med. 2016 May 17; 164(10):685-6. View abstract
  31. MacAllister RP, Lester McCully CM, Bacher J, Thomas ML, Cruz R, Wangari S, Warren KE. Minimally Invasive Lumbar Port System for the Collection of Cerebrospinal Fluid from Rhesus Macaques (Macaca mulatta). Comp Med. 2016; 66(4):349-52. View abstract
  32. Khaldun JS, Warren KE, Wen LS. Baltimore's Unrest: Perspectives From Public Health and Emergency Physician Leaders. Disaster Med Public Health Prep. 2016 Apr; 10(2):293-5. View abstract
  33. Shah NN, Cole DE, Lester-McCully CM, Wayne AS, Warren KE, Widemann BC. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. Invest New Drugs. 2016 Feb; 34(1):61-5. View abstract
  34. Wen LS, Warren KE, Tay S, Khaldun JS, O'Neill DL, Farrow OD. Public Health in the Unrest: Baltimore's Preparedness and Response After Freddie Gray's Death. Am J Public Health. 2015 Oct; 105(10):1957-9. View abstract
  35. Taylor IC, Hütt-Cabezas M, Brandt WD, Kambhampati M, Nazarian J, Chang HT, Warren KE, Eberhart CG, Raabe EH. Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition. J Neuropathol Exp Neurol. 2015 Aug; 74(8):778-90. View abstract
  36. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015 Jul; 21(7):827. View abstract
  37. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015 Jun; 21(6):555-9. View abstract
  38. Cole DE, Lester-McCully CM, Widemann BC, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. Cancer Chemother Pharmacol. 2015 May; 75(5):923-8. View abstract
  39. Lester McCully CM, Bacher J, MacAllister RP, Steffen-Smith EA, Saleem K, Thomas ML, Cruz R, Warren KE. Development of a cerebrospinal fluid lateral reservoir model in rhesus monkeys (Macaca mulatta). Comp Med. 2015 Feb; 65(1):77-82. View abstract
  40. Akshintala S, Marcus L, Warren KE, Murphy RF, Sissung TM, Srivastava A, Goodspeed WJ, Goodwin A, Brewer CC, Zalewski C, King KA, Kim A, Figg WD, Widemann BC. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatr Blood Cancer. 2015 Apr; 62(4):603-10. View abstract
  41. Wiener L, Sweeney C, Baird K, Merchant MS, Warren KE, Corner GW, Roberts KE, Lichtenthal WG. What do parents want to know when considering autopsy for their child with cancer? J Pediatr Hematol Oncol. 2014 Aug; 36(6):464-70. View abstract
  42. Steffen-Smith EA, Sarlls JE, Pierpaoli C, Shih JH, Bent RS, Walker L, Warren KE. Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma. Biomed Res Int. 2014; 2014:647356. View abstract
  43. Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, Kocak M, Chyla B, McKeegan E, Warren KE, Goldman S, Pollack IF, Fouladi M, Chen A, Giranda V, Boyett J, Kun L, Blaney SM. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol. 2014 Dec; 16(12):1661-8. View abstract
  44. Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, Ballester LY, Nazarian J, Eberhart CG, Rodriguez FJ. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2014 Jun 03; 2:59. View abstract
  45. Warren KE. Measuring the pons: a non-invasive biomarker for pediatric diffuse intrinsic pontine glioma. CNS Oncol. 2014 May; 3(3):181-3. View abstract
  46. Chittiboina P, Heiss JD, Warren KE, Lonser RR. Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr. 2014 Mar; 13(3):276-82. View abstract
  47. Steffen-Smith EA, Baker EH, Venzon D, Shandilya S, Bent RS, Warren KE. Measurements of the pons as a biomarker of progression for pediatric DIPG. J Neurooncol. 2014 Jan; 116(1):127-33. View abstract
  48. Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013 Dec 01; 119(23):4180-7. View abstract
  49. Warren KE. Novel therapeutic delivery approaches in development for pediatric gliomas. CNS Oncol. 2013 Sep; 2(5):427-35. View abstract
  50. Ballester LY, Wang Z, Shandilya S, Miettinen M, Burger PC, Eberhart CG, Rodriguez FJ, Raabe E, Nazarian J, Warren K, Quezado MM. Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas. Am J Surg Pathol. 2013 Sep; 37(9):1357-64. View abstract
  51. McCully CM, Pastakia D, Bacher J, Thomas ML, Steffen-Smith EA, Saleem K, Murphy RF, Walbridge S, Brinster L, Widemann BC, Warren KE. Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta). Comp Med. 2013 Aug; 63(4):355-60. View abstract
  52. Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep; 60(9):1397-401. View abstract
  53. Fangusaro J, Warren KE. Unclear standard of care for pediatric high grade glioma patients. J Neurooncol. 2013 Jun; 113(2):341-2. View abstract
  54. Warren KE. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2012; 2:205. View abstract
  55. Warren KE. Pediatric high-grade gliomas: survival at what cost? Transl Pediatr. 2012 Oct; 1(2):116-7. View abstract
  56. Hipp SJ, Steffen-Smith EA, Patronas N, Herscovitch P, Solomon JM, Bent RS, Steinberg SM, Warren KE. Molecular imaging of pediatric brain tumors: comparison of tumor metabolism using ¹8F-FDG-PET and MRSI. J Neurooncol. 2012 Sep; 109(3):521-7. View abstract
  57. Steffen-Smith EA, Venzon DJ, Bent RS, Hipp SJ, Warren KE. Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):774-9. View abstract
  58. Ko C, Kaushal A, Hammoud DA, Steffen-Smith EA, Bent R, Citrin D, Camphausen K, Warren KE. Role of early postradiation magnetic resonance imaging scans in children with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1252-1256. View abstract
  59. Warren K, Bent R, Wolters PL, Prager A, Hanson R, Packer R, Shih J, Camphausen K. A phase 2 study of pegylated interferon a-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma. Cancer. 2012 Jul 15; 118(14):3607-13. View abstract
  60. Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol. 2012 Mar; 14(3):326-32. View abstract
  61. Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012 Feb; 106(3):643-9. View abstract
  62. Martin S, Calabrese SK, Wolters PL, Walker KA, Warren K, Hazra R. Family functioning and coping styles in families of children with cancer and HIV disease. Clin Pediatr (Phila). 2012 Jan; 51(1):58-64. View abstract
  63. Hipp SJ, Steffen-Smith E, Hammoud D, Shih JH, Bent R, Warren KE. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol. 2011 Aug; 13(8):904-9. View abstract
  64. Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren KE, Meyer T, McNiff E, Balis FM, Widemann BC. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2012 Jan; 69(1):247-52. View abstract
  65. Steffen-Smith EA, Shih JH, Hipp SJ, Bent R, Warren KE. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neurooncol. 2011 Nov; 105(2):365-73. View abstract
  66. Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol. 2011 Jan 20; 29(3):324-9. View abstract
  67. Warren KE. Noninvasive assessment of pediatric brain tumors. Cancer Biol Ther. 2009 Oct; 8(20):1881-8. View abstract
  68. Fitzhugh CD, Wise B, Baird K, Tsokos M, Helman L, Mackall C, Savage SA, Warren KE. Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma. Pediatr Blood Cancer. 2009 Sep; 53(3):496-8. View abstract
  69. Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009 Dec; 65(1):137-42. View abstract
  70. Hayward RM, Patronas N, Baker EH, Vézina G, Albert PS, Warren KE. Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol. 2008 Oct; 90(1):57-61. View abstract
  71. Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008 Jun; 13(6):679-89. View abstract
  72. Wan MW, Warren K, Salmon MP, Abel KM. Patterns of maternal responding in postpartum mothers with schizophrenia. Infant Behav Dev. 2008 Sep; 31(3):532-8. View abstract
  73. Steffen-Smith EA, Wolters PL, Albert PS, Baker EH, Shimoda KC, Barnett AS, Warren KE. Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy. Childs Nerv Syst. 2008 Jul; 24(7):807-13. View abstract
  74. Warren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol. 2008 Aug; 62(3):433-7. View abstract
  75. Lonser RR, Warren KE, Butman JA, Quezado Z, Robison RA, Walbridge S, Schiffman R, Merrill M, Walker ML, Park DM, Croteau D, Brady RO, Oldfield EH. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg. 2007 Jul; 107(1):190-7. View abstract
  76. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer. 2005 Nov 01; 104(9):1968-74. View abstract
  77. Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol. 2005 Oct 20; 23(30):7646-53. View abstract
  78. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005 Sep 15; 104(6):1281-7. View abstract
  79. Warren KE. Advances in the assessment of childhood brain tumors and treatment-related sequelae. Curr Neurol Neurosci Rep. 2005 Mar; 5(2):119-26. View abstract
  80. Warren KE, Packer RJ. Current approaches to CNS tumors in infants and very young children. Expert Rev Neurother. 2004 Jul; 4(4):681-90. View abstract
  81. Solomon J, Warren K, Dombi E, Patronas N, Widemann B. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph. 2004 Jul; 28(5):257-65. View abstract
  82. Warren K, Gervais A, Aikin A, Egorin M, Balis FM. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother Pharmacol. 2004 Sep; 54(3):206-12. View abstract
  83. Warren KE. NMR spectroscopy and pediatric brain tumors. Oncologist. 2004; 9(3):312-8. View abstract